Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Summary

This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).

Timeline

Start

2019-11-29

Primary completion

2024-10-22

Completion

2024-11-01

Publications

• Negrier S, Mourey L, Dalban C, Gross-Goupil M, Flechon A, Escudier B, Barthelemy P, Oudard S, Colomba E, Thibault C, Ravaud A, Chevreau C, Boyle HJ, Blanc E, Chabaud S, Perol D, Albiges L, Flippot R; Groupe d'Etude des Tumeurs UroGenitale (Urogenital Tumor Study Group, GETUG) investigators. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET. Eur J Cancer. 2026 May 15;239:116712. doi: 10.1016/j.ejca.2026.116712. Epub 2026 Apr 1.

Drugs

Indications